AR061567A1 - Compuestos puros enantiomericamente para el tratamiento de desordenes proliferativos - Google Patents
Compuestos puros enantiomericamente para el tratamiento de desordenes proliferativosInfo
- Publication number
- AR061567A1 AR061567A1 ARP070102738A ARP070102738A AR061567A1 AR 061567 A1 AR061567 A1 AR 061567A1 AR P070102738 A ARP070102738 A AR P070102738A AR P070102738 A ARP070102738 A AR P070102738A AR 061567 A1 AR061567 A1 AR 061567A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- substituted
- unsubstituted
- alkylenehydroxy
- alkoxycarbonyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 230000002062 proliferating effect Effects 0.000 title 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 6
- 125000003118 aryl group Chemical group 0.000 abstract 4
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 150000002367 halogens Chemical class 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 3
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 abstract 2
- 125000005842 heteroatom Chemical group 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 239000000543 intermediate Substances 0.000 abstract 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 1
- 125000002861 (C1-C4) alkanoyl group Chemical group 0.000 abstract 1
- -1 C1-4 alkylenehydroxy Chemical group 0.000 abstract 1
- 102000003903 Cyclin-dependent kinases Human genes 0.000 abstract 1
- 108090000266 Cyclin-dependent kinases Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000003435 aroyl group Chemical group 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 239000002207 metabolite Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 125000006413 ring segment Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 239000011593 sulfur Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Communicable Diseases (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Virology (AREA)
- Vascular Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Se refiere además a intermediarios puros enantioméricamente de la misma, para procesos para la preparacion del compuesto puro enantioméricamente y sus intermediarios, y para una composicion farmacéutica que comprende el compuesto puro enantioméricamente. El compuesto de la formula (1) es util para el tratamiento de enfermedades o desordenes transmitidos por la inhibicion de la ciclina dependiente de la quinasa, como ser el cáncer. Reivindicacion 1: Compuesto puro enantioméricamente representado por la siguiente formula (1) o un metabolito, prodroga, sal farmacéuticamente aceptable, solvato farmacéuticamente aceptable o polimorfo de los mismos; en donde R1 es fenilo, que se encuentra no sustituido o sustituido por 1, 2, o 3 sustituyentes idénticos o diferentes seleccionados de: halogeno, nitro, ciano, alquilo C1-4, fluorometilo, difluorometilo, trifluorometilo, alcoxi C1-4, hidroxilo, carboxi, alcoxicarbonilo C1-4, alquilenohidroxilo C1-4, CONH2, CONR5R6, SO2NR5R6, cicloalquilo, NR5R6 y SR7; o es un heterociclo, que es un anillo saturado, parcialmente no saturado o aromático que contiene cinco o seis átomos en el anillo de los cuales 1, 2 o 3 son heteroátomos idénticos o diferentes seleccionados de: nitrogeno, oxígeno y azufre, y donde el heterociclo se encuentra no sustituido o sustituido por 1, 2, o 3 sustituyentes idénticos o diferentes seleccionados de: halogeno, nitro, ciano, alquilo C1-4, fluorometilo, difluorometilo, trifluorometilo, alcoxi C1-4, hidroxilo, carboxi, alcoxicarbonilo C1-4, alquilenohidroxilo C1-4, CONH2, CONR5R6, SO2NR5R6, cicloalquilo, NR5R6 y SR7; en donde R5 y R6 se seleccionan independientemente de: hidrogeno, alquilo C1-4, alcoxicarbonilo C1- 4, alquilcarbonilo C1-4, arilo; o R5 y R6 juntos con el átomo de nitrogeno al cual están unidos podrán formar un anillo de cinco o seis miembros que podrá contener opcionalmente un heteroátomo adicional; y R7 podrá seleccionarse de hidrogeno, alquilo C1-4, arilo, SR10 en donde R10 podrá seleccionarse de alquilo C1-4, alquilo o arilo; R2 y R3 se seleccionan independientemente de: halogeno, hidroxilo y OR8; en donde R8 se encuentra sustituido o no sustituido por alquilo C1-10, alcanoil C1- 4, aroil sustituido o no sustituido; R4 es alquilenohidroxilo C1-4; y R9 es hidrogeno o alquilo C1-4.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/IB2006/052002 WO2007148158A1 (en) | 2006-06-21 | 2006-06-21 | Enantiomerically pure flavone derivatives for the treatment of poliferative disorders and processes for their preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR061567A1 true AR061567A1 (es) | 2008-09-03 |
Family
ID=37744533
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070102738A AR061567A1 (es) | 2006-06-21 | 2007-06-21 | Compuestos puros enantiomericamente para el tratamiento de desordenes proliferativos |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US8563596B2 (es) |
| EP (1) | EP2046738B1 (es) |
| JP (1) | JP5498782B2 (es) |
| KR (1) | KR101209397B1 (es) |
| CN (1) | CN101472888B (es) |
| AR (1) | AR061567A1 (es) |
| AU (1) | AU2006344987B8 (es) |
| BR (1) | BRPI0621777A2 (es) |
| CA (1) | CA2655789C (es) |
| DK (1) | DK2046738T3 (es) |
| ES (1) | ES2491140T3 (es) |
| IL (1) | IL195850A0 (es) |
| MX (1) | MX2008016398A (es) |
| NZ (1) | NZ574266A (es) |
| PT (1) | PT2046738E (es) |
| TW (1) | TWI461420B (es) |
| WO (1) | WO2007148158A1 (es) |
| ZA (1) | ZA200810756B (es) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7915301B2 (en) | 2002-07-08 | 2011-03-29 | Piramal Life Science Limited | Inhibitors of cyclin dependent kinases and their use |
| US7884127B2 (en) | 2002-07-08 | 2011-02-08 | Pirimal Life Sciences Ltd. | Inhibitors of cyclin dependent kinases and their use |
| JP5006396B2 (ja) | 2006-07-07 | 2012-08-22 | ピラマル・ライフ・サイエンシーズ・リミテッド | ピロリジン置換フラボンのエナンチオ選択的合成 |
| TWI461194B (zh) | 2009-05-05 | 2014-11-21 | Piramal Entpr Ltd | 吡咯啶取代黃酮作為輻射致敏劑 |
| US9155724B2 (en) | 2010-02-05 | 2015-10-13 | Whitehead Institute For Biomedical Research | Combination methods for treatment of disease |
| AU2010346973A1 (en) | 2010-02-26 | 2012-10-18 | Piramal Enterprises Limited | Pyrrolidine substituted flavones for the treatment of inflammatory disorders |
| WO2011121505A1 (en) | 2010-03-29 | 2011-10-06 | Piramal Life Sciences Limited | Cytokine inhibitors |
| WO2012069972A1 (en) | 2010-11-19 | 2012-05-31 | Piramal Life Sciences Limited | A pharmaceutical combination for the treatment of breast cancer |
| TW201242597A (en) | 2011-03-14 | 2012-11-01 | Piramal Life Sciences Ltd | A synergistic pharmaceutical combination for the treatment of pancreatic cancer |
| UY34013A (es) * | 2011-04-13 | 2012-11-30 | Astrazeneca Ab | ?compuestos de cromenona con actividad anti-tumoral?. |
| TW201300105A (zh) | 2011-05-31 | 2013-01-01 | Piramal Life Sciences Ltd | 治療頭頸鱗狀細胞癌之相乘藥物組合物 |
| MX2013014950A (es) | 2011-06-24 | 2014-04-16 | Piramal Entpr Ltd | Compuestos para el tratamiento del cancer asociado con el papilomavirus humano. |
| TW201338774A (zh) | 2012-01-13 | 2013-10-01 | Piramal Entpr Ltd | 口腔粘膜炎預防或治療化合物 |
| EP2877461B1 (en) | 2012-07-27 | 2018-05-09 | Emory University | Heterocyclic flavone derivatives, compositions, and methods related thereto |
| KR101389407B1 (ko) * | 2012-08-27 | 2014-05-27 | 한림대학교 산학협력단 | 척추 고정용 임플란트 |
| WO2014049515A1 (en) * | 2012-09-25 | 2014-04-03 | Piramal Enterprises Limited | Pyrrolidine substituted flavones for treatment of renal cystic diseases |
| JP6479670B2 (ja) | 2012-11-05 | 2019-03-06 | エモリー ユニバーシティー | ７，８−ジヒドロキシフラボンおよび７，８−置換フラボン誘導体、組成物、およびそれらに関連する方法 |
| US20150353542A1 (en) | 2013-01-14 | 2015-12-10 | Amgen Inc. | Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture |
| WO2014128524A1 (en) * | 2013-02-19 | 2014-08-28 | Piramal Enterprises Limited | An improved process for preparation of an intermediate of the pyrrolidine substituted flavones |
| WO2014128523A1 (en) * | 2013-02-19 | 2014-08-28 | Piramal Enterprises Limited | A process for preparation of an intermediate of the pyrrolidine substituted flavones |
| WO2014140695A1 (en) * | 2013-03-15 | 2014-09-18 | Piramal Enterprises Limited | Solid oral formulation of a pyrrolidine substituted flavone compound |
| AR096892A1 (es) | 2013-07-12 | 2016-02-03 | Piramal Entpr Ltd | Una combinación farmacéutica para el tratamiento del melanoma |
| WO2015181737A1 (en) | 2014-05-28 | 2015-12-03 | Piramal Enterprises Limited | Pharmaceutical combination for the treatment of cancer |
| US11135198B2 (en) | 2016-03-28 | 2021-10-05 | Presage Biosciences, Inc. | Pharmaceutical combinations for the treatment of cancer |
| US11987589B2 (en) | 2018-08-07 | 2024-05-21 | Emory University | Heterocyclic flavone derivatives, compositions, and methods related thereto |
| EA202190360A1 (ru) * | 2018-08-14 | 2021-07-15 | Мей Фарма, Инк | Комбинированная терапия |
| US20220040324A1 (en) | 2018-12-21 | 2022-02-10 | Daiichi Sankyo Company, Limited | Combination of antibody-drug conjugate and kinase inhibitor |
| JP7555350B2 (ja) * | 2019-04-11 | 2024-09-24 | メイ ファーマ，インク． | ボルシクリブ多形、並びにそれを作製する方法及び使用する方法 |
| CN110028475B (zh) * | 2019-05-13 | 2022-07-01 | 中国药科大学 | 基于苯并吡喃结构的新型cdk9抑制剂、其制备方法及应用 |
| EP4247806A4 (en) * | 2020-11-19 | 2024-11-13 | MEI Pharma, Inc. | TREATMENT OF KRAS-MUTANT CANCERS |
| CN114957182B (zh) * | 2022-03-30 | 2024-03-15 | 中国药科大学 | 一类含有黄酮骨架结构的usp8抑制剂及其应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IN164232B (es) | 1986-04-11 | 1989-02-04 | Hoechst India | |
| JP3451099B2 (ja) | 1991-12-06 | 2003-09-29 | 株式会社日立製作所 | 外部記憶サブシステム |
| US7271193B2 (en) * | 2002-07-08 | 2007-09-18 | Nicholas Piramal India, Ltd. | Inhibitors of cyclin-dependent kinases and their use |
| TWI331034B (en) * | 2002-07-08 | 2010-10-01 | Piramal Life Sciences Ltd | Inhibitors of cyclin-dependent kinases and their use |
| US8017651B2 (en) | 2002-11-22 | 2011-09-13 | Bionexus, Ltd. | Compositions and methods for the treatment of HIV-associated fat maldistribution and hyperlipidemia |
-
2006
- 2006-06-21 US US12/305,815 patent/US8563596B2/en active Active
- 2006-06-21 EP EP06765803.9A patent/EP2046738B1/en active Active
- 2006-06-21 JP JP2009515971A patent/JP5498782B2/ja active Active
- 2006-06-21 ES ES06765803.9T patent/ES2491140T3/es active Active
- 2006-06-21 DK DK06765803.9T patent/DK2046738T3/da active
- 2006-06-21 CA CA2655789A patent/CA2655789C/en active Active
- 2006-06-21 NZ NZ574266A patent/NZ574266A/en unknown
- 2006-06-21 BR BRPI0621777-0A patent/BRPI0621777A2/pt not_active IP Right Cessation
- 2006-06-21 AU AU2006344987A patent/AU2006344987B8/en active Active
- 2006-06-21 CN CN200680055077.2A patent/CN101472888B/zh active Active
- 2006-06-21 WO PCT/IB2006/052002 patent/WO2007148158A1/en not_active Ceased
- 2006-06-21 MX MX2008016398A patent/MX2008016398A/es not_active Application Discontinuation
- 2006-06-21 PT PT67658039T patent/PT2046738E/pt unknown
- 2006-06-21 KR KR1020097001021A patent/KR101209397B1/ko not_active Expired - Fee Related
-
2007
- 2007-06-20 TW TW096122190A patent/TWI461420B/zh not_active IP Right Cessation
- 2007-06-21 AR ARP070102738A patent/AR061567A1/es unknown
-
2008
- 2008-12-10 IL IL195850A patent/IL195850A0/en active IP Right Grant
- 2008-12-19 ZA ZA2008/10756A patent/ZA200810756B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA200810756B (en) | 2013-05-29 |
| CA2655789A1 (en) | 2007-12-27 |
| PT2046738E (pt) | 2014-08-29 |
| WO2007148158A1 (en) | 2007-12-27 |
| AU2006344987A1 (en) | 2007-12-27 |
| EP2046738B1 (en) | 2014-06-11 |
| TW200813030A (en) | 2008-03-16 |
| MX2008016398A (es) | 2009-01-21 |
| JP5498782B2 (ja) | 2014-05-21 |
| JP2009541294A (ja) | 2009-11-26 |
| ES2491140T3 (es) | 2014-09-05 |
| KR101209397B1 (ko) | 2012-12-06 |
| CN101472888A (zh) | 2009-07-01 |
| AU2006344987B8 (en) | 2013-07-11 |
| NZ574266A (en) | 2011-10-28 |
| BRPI0621777A2 (pt) | 2013-03-12 |
| AU2006344987B2 (en) | 2012-11-15 |
| US20100179210A1 (en) | 2010-07-15 |
| CN101472888B (zh) | 2014-02-26 |
| HK1126761A1 (en) | 2009-09-11 |
| US8563596B2 (en) | 2013-10-22 |
| CA2655789C (en) | 2014-04-01 |
| TWI461420B (zh) | 2014-11-21 |
| AU2006344987A2 (en) | 2009-01-29 |
| EP2046738A1 (en) | 2009-04-15 |
| KR20090023705A (ko) | 2009-03-05 |
| DK2046738T3 (da) | 2014-08-04 |
| IL195850A0 (en) | 2009-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR061567A1 (es) | Compuestos puros enantiomericamente para el tratamiento de desordenes proliferativos | |
| ES2509820T3 (es) | Derivados de indazol como inhibidores de la cinasa para el tratamiento del cáncer | |
| MX2021009763A (es) | Derivados de 3-(1-oxo-5-(piperidin-4-il)isoindolin-2-il)piperidina -2,6-diona y usos de los mismos. | |
| CY1118879T1 (el) | Ενωσεις τριαζινης ως αναστολεις κινασης ρ13 και mtor | |
| EA201070864A1 (ru) | Новые гетероциклические соединения | |
| AR118805A2 (es) | Terapia de combinación para el tratamiento de la diabetes | |
| EP4295852A3 (en) | Piperidine derivatives as inhibitors of cyclin dependent kinase 7 (cdk7) | |
| CY1108908T1 (el) | Ενωσεις κινολινονης - καρβοξαμιδης ως αγωνιστες υποδοχεων 5-ητ4 | |
| AR070531A1 (es) | Inhibidores de cinasa pim y metodos para su uso | |
| AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
| AR068115A1 (es) | Derivado del acido pirazolcarboxilico metodo de produccion del mismo y fungicida | |
| CR20200418A (es) | Inhibidores de orginasa y sus mètodos de uso antecedentes | |
| EA201490722A1 (ru) | ПРОИЗВОДНЫЕ ЭТИНИЛА В КАЧЕСТВЕ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ МЕТАБОТРОПНОГО РЕЦЕПТОРА ГЛУТАМАТА mGluR5 | |
| AR048362A1 (es) | Derivados de tetrahidronaftiridina y proceso para la preparacion de los mismos | |
| PE20060937A1 (es) | Derivados de sulfonilbencimidazol como agonistas del receptor cannabinoide 2 (cb2) | |
| PE20200445A1 (es) | Inhibidores pirazolicos de magl | |
| AR069607A1 (es) | Inhibidores de la estearoil-coa desaturasa | |
| PH12012500867A1 (en) | Ethynyl derivatives | |
| CU20210023A7 (es) | Inhibidores fenil sustituidos de la piridinil 1,2-oxaborolan-2-ol fosfodiesterasa 4 | |
| PE20110213A1 (es) | Derivados de indolinona como inhibidores de quinasa | |
| PE20161369A1 (es) | Inhibidores de monoacilglicerol aciltransferasa 2 (mgat2) de dihidropiridinona sustituidos con tetrazolona | |
| AR056103A1 (es) | Compuestos de(piran-piperidinil)benzimidazol, composiciones farmaceuticas que los comprenden, proceso de preparacion y usos en el tratamiento de afecciones mediadas por agonistas del receptor muscarinico m1 | |
| NZ767900A (en) | Pyrazo-tetrahydroisoquinoline derivatives as dopamine d1 receptor positive modulators | |
| AR097721A1 (es) | Derivados de etinilo | |
| AR047531A1 (es) | Derivados 1h-tieno(2,3-c)pirazol utiles como inhibidores de quinasa |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |